Document:

Description of Certain Compensatory Arrangements

 Exhibit 10.20 
 Description of Certain Compensatory Arrangements 
 Executive Compensation 
 Varian Medical Systems, Inc. (the “Company”) does not have a written
employment agreement with any of its named executive officers (determined by reference to the Company's 2009 proxy statement dated December 29, 2008). The current annual base salary for each of the Company’s Principal Executive Officer,
Principal Financial Officer, and the other named executive officers is as follows: 
  

				
	 Name
	  	Current
Base Salary
	 Timothy E. Guertin,
Corporate President and Chief Executive Officer
	  	$	875,000
	 Elisha W. Finney,
Corporate Senior Vice President, Finance and Chief Financial Officer
	  	$	520,000
	 Dow R. Wilson,
Corporate Executive Vice President and President, Oncology Systems
	  	$	606,000
	 Robert H. Kluge,
Corporate Senior Vice President and President, X-ray Products
	  	$	412,000
	 John W. Kuo,
Corporate Vice President, General Counsel and Corporate Secretary
	  	$	362,000

 On November 13, 2009, the Compensation and Management Development Committee set
the performance goals for fiscal year 2010 under the Company’s Management Incentive Plan (“MIP”) for the named executive officers and certain other executives. In the case of Timothy E. Guertin, Elisha W. Finney and John W. Kuo,
payments under the MIP will be based 50% on return on sales (“ROS”) for the Company as a whole and 50% on a percentage growth of earnings before interest and taxes (“EBIT”) for the Company as a whole. In the case of Dow R.
Wilson, payment under the MIP will be based 25% on return on sales (“ROS”) for the Company as a whole, 25% on the percentage growth in EBIT for the Company as a whole, 25% on return on sales (“ROS”) for the Oncology Systems
business segment and 25% on the percentage growth in EBIT for the Oncology Systems business segment. In the case of Robert H. Kluge, payment under the MIP will be based 25% on return on sales (“ROS”) for the Company as a whole, 25% on the
percentage growth in EBIT for the Company as a whole, 25% on return on sales (“ROS”) for the X-ray Products business segment and 25% on the percentage growth in EBIT for the X-ray Products business segment. Payment under the MIP may vary
from $0 to 220% of base salary based upon achievement under these performance goals. 
 Set forth below are the percentages of
base salary each of these individuals would receive if the target and maximum levels under the MIP are achieved: 
  

							
	 Name
	  	Target	 	 	Maximum	 
	 Timothy E. Guertin
	  	110	% 	 	220	% 
	 Elisha W. Finney
	  	80	% 	 	160	% 
	 Dow R. Wilson
	  	80	% 	 	160	% 
	 Robert H. Kluge
	  	60	% 	 	120	% 
	 John W. Kuo
	  	60	% 	 	120	% 

 These executive officers have also been extended certain perquisites, such as use of a
leased automobile under the Company’s Executive Car Program. Under the Executive Car Program, the Company provides a leased vehicle costing up to $82,000 for the Chief Executive Officer and leased vehicles costing up to $68,000 for the other
named executive officers. Insurance, maintenance expenses and fuel costs are also included in the Executive Car Program. Participants have an option to purchase the car at the end of its three-year lease period or upon retirement at the lower of its
depreciated book value or its fair market value (based on the Kelley Blue Book Auto Market Report wholesale value). 
 The
Company does not permit its executives to use the Company’s fractionally owned aircraft for purely personal trips. However, the Company allows and includes in an executive’s compensation, as applicable, aircraft use attributable to
permitted spousal use of the fractionally owned aircraft for business purposes and spousal travel on commercial airplanes deemed valuable and appropriate for business purposes. 
 The Company reimburses executive officers and non-executive officers for financial planning, estate planning, tax planning, tax return
preparation and financial counseling services (to a maximum of $6,500 per year and unlimited for the Chief Executive Officer). The Company also reimburses certain individuals, including all executive officers and non-executive officers, for annual
medical examinations (up to a maximum of $4,000 per year). 
 Additionally, for the benefit of the executives, the Company also
provides a Company supplemental contribution match representing retirement contributions which could not be contributed to the executives’ qualified retirement accounts due to Internal Revenue Code limitations. The Company also permits
executives to participate in the Company’s Deferred Compensation Plan, under which they may defer up to 50% of their base salaries and up to 100% of their cash incentives, and in compensation and benefit programs generally available to all
other U.S. employees, such as the Company’s Employee Incentive Plan, Employee Stock Purchase Plan, 401(k) Retirement Program and supplemental life and disability insurance programs. 
 Mr. Wilson’s employment is governed by an offer letter that provides for certain additional compensation. Please refer to Exhibits
10.18 and 10.19 of the Company’s Annual Report on Form 10-K for the fiscal year ended October 2, 2009. 
 Compensation of Directors 
 Annual Cash Compensation.    Each non-employee director
receives an annual retainer of $45,000, except that the lead director receives an annual retainer of $60,000. The chairs of the Compensation and Management Development Committee and the Nominating and Corporate Governance Committee also receive an
additional $10,000 annual retainer for serving in these positions, and the chair of the Audit Committee receives an additional $15,000. Each non-employee director also receives $2,000 for each Board meeting attended ($1,000 if the Board meeting was
an in-person meeting and the director attended by telephone or video conference), and $1,500 for each committee meeting attended ($750 if the committee meeting was an in-person meeting and the director attended by telephone or video conference).
Directors who are employees receive no compensation for their services as directors. All directors, however, receive reimbursement for out-of-pocket expenses of the directors’ and the directors’ spouses (including tax reimbursement for
spousal expenses) associated with attending Board and committee meetings and for expenses related to directors’ continuing education programs. Non-employee directors may elect to receive cash compensation as full-value shares of the
Company’s common stock, at a value

 
equal to the fair market value of the Company’s common stock on the date that the foregone cash compensation otherwise would have been paid. Directors may alternatively elect to defer their
retainer and/or meeting fees under the Company’s Deferred Compensation Plan. 
 Equity Compensation. New
non-employee directors do not receive initial equity awards, but each continuing non-employee director receives an annual grant of non-qualified stock options to purchase 5,000 shares of common stock and an annual grant of Deferred Stock Units
having a fair market value on the date of grant of $100,000, based on the fair market value (i.e., the closing price) of our common stock on the date of grant. 
 Compensation for Levy as a Non-Executive Employee 
 In his role as a
non-executive employee of the Company, Dr. Levy receives the following compensation: 
  

	 	•	 	 base salary of $160,000; 

  

	 	•	 	 provision of a leased office space at a fair market value; 

  

	 	•	 	 provision of a part-time administrator; and 

  

	 	•	 	 eligibility for the Corporation’s non-executive employee health and welfare benefit plans, subject to his election and contributions towards those
benefit plans. 

 Dr. Levy is not eligible to participate in the Company’s Management Incentive Plan
and in any executive perquisite programs, including the Executive Car Program and reimbursement for executive physicals. He is also not eligible for equity awards, paid personal leave accrual or for any supplemental retirement contributions in
excess of the Company’s matching contributions under the Varian Medical Systems, Inc. Retirement Plan (the Company’s 401(k) Plan). 
 In his role as a non-executive employee of the Company (and in addition to his responsibilities as Chairman of the Board), Dr. Levy provides on-going advice and counsel to the management of the
Company on strategic business and technological matters, and has involvement with investor groups and key customers.Amendment to Amended and Restated Credit Agreement

 Exhibit 10.33 
 AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT 
 This AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of July 14, 2009, is entered into by and between VARIAN MEDICAL SYSTEMS, INC., a Delaware corporation (the
“Borrower”), and BANK OF AMERICA, N.A. (the “Lender”). 
 RECITALS 
 A. The Borrower and the Lender are party to that certain Amended and Restated Credit Agreement dated as of November 10, 2008 (the
“Credit Agreement”), pursuant to which the Lender has extended certain credit facilities to the Borrower. 
 B.
The Borrower has requested that the Lender agree to certain amendments with respect to the Credit Agreement, and the Lender has agreed to such request, subject to the terms and conditions of this Amendment. 
 NOW, THEREFORE, for valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby agree as
follows: 
 1. Defined Terms. Unless otherwise defined herein, capitalized terms used herein shall have the meanings, if
any, assigned to such terms in the Credit Agreement. As used herein, “Amendment Documents” means this Amendment, the Credit Agreement (as amended by this Amendment), and each certificate and other document executed and delivered by
the Borrower pursuant to Section 5 hereof. 
 2. Amendments to Credit Agreement. Subject to the terms and
conditions hereof and with effect from and after the Effective Date, the Credit Agreement shall be amended as follows: 
 (a)
Section 1.01 of the Credit Agreement shall be amended by deleting the definition “Commitment” and replacing it with the following: 
 “Commitment” means the obligation of the Lender to make Loans and L/C Credit Extensions hereunder in an
aggregate principal amount at any one time (i) not to exceed One Hundred Fifty Million Dollars ($150,000,000), as such amount may be adjusted from time to time in accordance with this Agreement; provided, (ii) that on any day as
there may exist outstanding loans or extensions of credit under the Offshore Overdraft Facility, or the Offshore Overdraft Facility shall be in effect, the “Commitment” hereunder shall automatically and without further notice or action by
the Lender be reduced for such day by $30,000,000 below the Commitment otherwise determined under clause (i) of this definition. 
  

 1 

 (b) Section 1.01 of the Credit Agreement shall be further amended by adding the
following definition in appropriate alphabetical order: 
 “Offshore Overdraft Facility” means a
Japanese yen revolving offshore overdraft facility provided by the Lender or its Affiliates to or for the benefit of Varian Medical Systems K.K. or its successors. 
 (c) Section 8.01(e) of the Credit Agreement shall be amended by adding the following at the end thereof: 
 “(iii) there occurs any event of default, termination event, or other event or circumstance under any document or agreement evidencing the Offshore Overdraft Facility, the effect of which default or
other event is to cause, or permit the Lender or its Affiliate to cause, with the giving of notice if required, any and all indebtedness and other obligations to be demanded or to become due or such facility to be terminated; or” 
 3. Representations and Warranties. The Borrower hereby represents and warrants to the Lender as follows: 
 (a) After giving effect to this Amendment, no Default or Event of Default has occurred and is continuing. 
 (b) The execution, delivery and performance by the Borrower of this Amendment and the other Amendment Documents have been duly authorized by
all necessary corporate and other action and do not and will not require any registration with, consent or approval of, or notice to or action by, any Person (including any Governmental Authority) in order to be effective and enforceable.

 (c) All representations and warranties of the Borrower contained in Article V of the Credit Agreement are true
and correct in all material respects on and as of the Effective Date after giving effect to this Amendment, except to the extent that any such representation and warranty specifically relates to an earlier date, in which case they shall be
true and correct in all material respects as of such earlier date after giving effect to this Amendment. 
 (d) The Borrower is
entering into this Amendment on the basis of its own investigation and for its own reasons, without reliance upon the Lender or any other Person. 
 (e) The obligations of the Borrower under the Credit Agreement and each other Loan Document are not subject to any defense, counterclaim, set-off, right of recoupment, abatement or other claim.

 4. Effective Date. This Amendment will become effective when each of the conditions precedent set forth in this
Section 4 has been satisfied (the “Effective Date”): 
 (i) The Lender shall have
received from the Borrower a duly executed original (or, if elected by the Lender, an executed facsimile copy) counterpart to this Amendment. 
  

 2 

 (ii) The Lender shall have received from the Borrower a certificate signed
by the secretary or assistant secretary of the Borrower, dated the Effective Date, in form and substance satisfactory to the Lender, and certifying evidence of the authorization of the execution, delivery and performance by the Borrower of this
Amendment. 
 (iii) The Lender shall have received, in form and substance satisfactory to it, such additional
approvals, consents, documents and other information as the Lender shall reasonably request. 
 5. Reservation of Rights.
The Borrower acknowledges and agrees that neither the execution nor the delivery by the Lender of this Amendment shall (a) be deemed to create a course of dealing or otherwise obligate the Lender to execute similar amendments, consents or
waivers under the same or similar circumstances in the future or (b) be deemed to create any implied waiver of any right or remedy of the Lender with respect to any term or provision of any Loan Document. 
 6. Miscellaneous. 
 (a) Except as expressly amended or modified hereby, all terms, covenants and provisions of the Credit Agreement are and shall remain in full force and effect and all references therein to such Credit Agreement shall henceforth refer to the
Credit Agreement as modified by this Amendment. This Amendment shall be deemed incorporated into, and a part of, the Credit Agreement. 
 (b) This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. No third party beneficiaries are intended in connection with this Amendment. 
 (c) THIS AMENDMENT IS SUBJECT TO THE PROVISIONS OF SECTION 9.13 OF THE CREDIT AGREEMENT RELATING TO GOVERNING LAW, SUBMISSION
TO JURISDICTION AND WAIVER OF VENUE AND THE RIGHT TO TRIAL BY JURY, THE PROVISIONS OF WHICH ARE BY THIS REFERENCE INCORPORATED HEREIN IN FULL. 
 (d) This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Each of
the parties hereto understands and agrees that this document (and any other document required herein) may be delivered by any party hereto or thereto either in the form of an executed original or an executed original sent by facsimile transmission
to be followed promptly by mailing of a hard copy original, and the receipt by the Lender of a facsimile transmitted document purportedly bearing the signature of the Borrower or one of the other parties hereto, as applicable, shall bind the
Borrower or such other party, respectively, with the same force and effect as the delivery of a hard copy original. Any failure by the Lender to receive the hard copy executed original of such document shall not diminish the binding effect of
receipt of the facsimile transmitted executed original of such document of the party whose hard copy page was not received by the Lender. 
  

 3 

 (e) This Amendment contains the entire and exclusive agreement of the parties hereto with
reference to the matters discussed herein. This Amendment supersedes all prior drafts and communications with respect thereto. This Amendment may not be amended except by a written agreement executed by the Borrower and the Lender. 
 (f) If any term or provision of this Amendment shall be deemed prohibited by or invalid under any applicable law, such provision shall be
invalidated without affecting the remaining provisions of this Amendment or the Credit Agreement, respectively. 
 (g) The
Borrower covenants to pay to or reimburse the Lender, upon demand, for all reasonable and documented out-of-pocket costs and expenses incurred in connection with the development, preparation, negotiation, execution and delivery, and enforcement of
this Amendment. 
 (h) This Amendment shall constitute a “Loan Document” under and as defined in the Credit Agreement.

 [Remainder of this page intentionally left blank] 
  

 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed
as of the date first above written. 
  

			
	 VARIAN MEDICAL SYSTEMS, INC.

		
	 By:
	 	 /s/ Elisha W. Finney

	 Name:
	 	Elisha W. Finney
	 Title:
	 	Corporate Senior Vice President and Chief Financial Officer
		
	By:	 	 /s/ Franco N. Palomba

	Name:	 	Franco N. Palomba
	Title:	 	Vice President Finance-Treasurer

  

 Signature Page 1 to Amendment to Amended and Restated Credit Agreement

			
	 BANK OF AMERICA, N.A.

		
	By:	 	 /s/ John C. Plecque

	Name:	 	John C. Plecque
	Title:	 	Senior Vice President

  

 Signature Page 2 to Amendment to Amended and Restated Credit Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]